Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | GAPDH | P04406 | 1/20 | 0.39 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.39 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.39 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.39 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5139788 | 1.00 | MAPT (0.52) | MAPTPOLBKMT2AMEN1USP2 | |
| SCHEMBL4960765 | 1.00 | MAPT (0.52) | MAPTPOLBKMT2AMEN1USP2 | |
| SCHEMBL4962623 | 1.00 | MAPT (0.52) | MAPTPOLBKMT2AMEN1USP2 | |
| SCHEMBL8512702 | 0.96 | MAPT (0.55) | MAPTPOLBKMT2AMEN1USP2 | |
| SCHEMBL9137960 | 0.96 | MAPT (0.55) | MAPTPOLBKMT2AMEN1USP2 | |
| SCHEMBL8512700 | 0.96 | MAPT (0.55) | MAPTPOLBKMT2AMEN1USP2 | |
| SCHEMBL11073044 | 0.96 | MAPT (0.55) | MAPTPOLBKMT2AMEN1USP2 | |
| SCHEMBL3060466 | 0.90 | MAPT (0.47) | MAPTPOLBKMT2AMEN1USP2 | |
| SCHEMBL8892883 | 0.86 | NT5E (0.46) | MAPTPOLBKMT2AMEN1USP2 | |
| SCHEMBL8892887 | 0.86 | NT5E (0.46) | MAPTPOLBKMT2AMEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391218-B1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-10398781-B2 | Conjugate based systems for controlled drug delivery | SMARTCELLS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180064824-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2018-03-08 | — | — | US | disclosed |
| US-9745355-B2 | Binding-site modified lectins and uses thereof | SMARTCELLS, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9579391-B2 | Conjugate based systems for controlled drug delivery | SMARTCELLS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20170022262-A1 | CRYSTALLINE INSULIN-CONJUGATES | SMARTCELLS, INC. (US) | 2017-01-26 | — | — | US | disclosed |
| US-9463249-B2 | Crystalline insulin-conjugates | SMARTCELLS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| EP-2391646-B1 | CRYSTALLINE INSULIN-CONJUGATES | SMARTCELLS INC (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20160193351-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-9265838-B2 | Conjugate based systems for controlled drug delivery | SMART CELLS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20130324702-A1 | RECOMBINANT LECTINS, BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SMARTCELLS, INC. | 2013-12-05 | — | — | US | disclosed |
| US-8569231-B2 | Soluble non-depot insulin conjugates and uses thereof | SMARTCELLS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130190475-A1 | DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | SMARTCELLS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130131310-A1 | DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | SMARTCELLS, INC. | 2013-05-23 | — | — | US | disclosed |
| US-20120046223-A1 | EXOGENOUSLY TRIGGERED CONTROLLED RELEASE MATERIALS AND USES THEREOF | SMARTCELLS, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20120010134-A1 | SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF | SMARTCELLS, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20110301083-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. | 2011-12-08 | — | — | US | disclosed |
| US-20110281792-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SMARTCELLS, INC. | 2011-11-17 | — | — | US | disclosed |
| US-20110281791-A1 | CRYSTALLINE INSULIN-CONJUGATES | SMARTCELLS, INC. | 2011-11-17 | — | — | US | disclosed |
| US-20110275560-A1 | SYNTHETIC CONJUGATES AND USES THEREOF | SMARTCELLS, INC. | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275560-A1 | SYNTHETIC CONJUGATES AND USES THEREOF | SLC2A4, SLC2A8, CD44 | MAPT 3495/4885POLB 4617/4885KMT2A 1875/4885 |
| US-10398781-B2 | Conjugate based systems for controlled drug delivery | SI, CSGALNACT1, CD44 | MAPT 2050/4885POLB 4845/4885KMT2A 3261/4885 |
| US-20130190475-A1 | DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | ALK, ACVR1, ACVRL1 | MAPT 2550/4885POLB 4457/4885KMT2A 994/4885 |
| US-20120010134-A1 | SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF | GPR119, IAPP, IRS1 | MAPT 3646/4885POLB 4856/4885KMT2A 1976/4885 |
| US-20110301083-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SI, CSGALNACT1, CD44 | MAPT 2050/4885POLB 4845/4885KMT2A 3261/4885 |
| US-20110281791-A1 | CRYSTALLINE INSULIN-CONJUGATES | IAPP, INSR, GPR119 | MAPT 363/4885POLB 4049/4885KMT2A 4507/4885 |
| US-20110281792-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SIGLEC7, SIGLEC9, LGALS3BP | MAPT 4266/4885POLB 4846/4885KMT2A 3096/4885 |
| US-20180064824-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SI, CSGALNACT1, CD44 | MAPT 2050/4885POLB 4845/4885KMT2A 3261/4885 |
| US-20130131310-A1 | DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | ALK, ABL1, ERBB3 | MAPT 1797/4885POLB 4441/4885KMT2A 1816/4885 |
| US-20170022262-A1 | CRYSTALLINE INSULIN-CONJUGATES | IAPP, INSR, GPR119 | MAPT 363/4885POLB 4049/4885KMT2A 4507/4885 |
| US-20130324702-A1 | RECOMBINANT LECTINS, BINDING-SITE MODIFIED LECTINS AND USES THEREOF | MASP2, LGALS3BP, SIGLEC7 | MAPT 4352/4885POLB 4858/4885KMT2A 3541/4885 |
| US-20160193351-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SI, CSGALNACT1, CD44 | MAPT 2050/4885POLB 4845/4885KMT2A 3261/4885 |
| US-20120046223-A1 | EXOGENOUSLY TRIGGERED CONTROLLED RELEASE MATERIALS AND USES THEREOF | CD63, NSF, MSN | MAPT 3265/4885POLB 4805/4885KMT2A 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.